Trade

with

Momenta Pharmaceuticals Inc
(NASDAQ: MNTA)
AdChoices
11.02
+0.02
+0.18%
After Hours :
11.02
0.00
0.00%

Open

11.03

Previous Close

11.00

Volume (Avg)

325.59k (455.59k)

Day's Range

10.92-11.13

52Wk Range

9.38-19.90

Market Cap.

582.00M

Dividend Rate ( Yield )

-

Beta

2.01

Shares Outstanding

52.81M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 35.47M

    • Net Income

    • -108.41M

    • Market Cap.

    • 582.00M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -240.87

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.01

    • Forward P/E

    • 5.09

    • Price/Sales

    • 12.48

    • Price/Book Value

    • 2.58

    • Price/Cash flow

    • -6.41

      • EBITDA

      • -100.24M

      • Return on Capital %

      • -34.84

      • Return on Equity %

      • -40.33

      • Return on Assets %

      • -34.84

      • Book Value/Share

      • 4.27

      • Shares Outstanding

      • 52.81M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 16.67

        • Credit Rating

        • -

        • Analysts

        • 4

        • EPS Estimate

        • 2.04

        • Cashflow Estimate

        • 1.78

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 151.10

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 19.47

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 81.31

            • 64.72

            • Pre-Tax Margin

            • -240.87

            • 13.77

            • Net Profit Margin

            • -240.87

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -123.60

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 11.04

              • 1.52

              • Quick Ratio

              • 10.91

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.19

              • 1.91

              • Book Value/Share

              • 4.27

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.27

                • 65.79

                • P/E Ratio 5-Year High

                • -12.33

                • 237.47

                • P/E Ratio 5-Year Low

                • -4.09

                • 19.71

                • Price/Sales Ratio

                • 12.71

                • 3.69

                • Price/Book Value

                • 2.63

                • 3.46

                • Price/Cash Flow Ratio

                • -6.41

                • 22.12

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -40.33

                    (-6.40)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -34.84

                    (-3.60)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -40.33

                    (-5.60)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • -

                  • 1.80

                  • Asset Turnover

                  • 0.14

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -109.59M
                  Operating Margin
                  -309.01
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -6.41
                  Ownership

                  Institutional Ownership

                  87.33%

                  Top 10 Institutions

                  47.79%

                  Mutual Fund Ownership

                  41.57%

                  Float

                  87.20%

                  5% / Insider Ownership

                  7.21%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • PrimeCap Odyssey Aggressive Growth Fund

                  •  

                    1,769,283

                  • 109.81

                  • 3.35

                  • T. Rowe Price Small Cap Value Fund

                  •  

                    1,459,500

                  • 0.40

                  • 2.77

                  • SPDR® S&P Biotech ETF

                  •  

                    1,230,809

                  • -1.93

                  • 2.26

                  • Fidelity® Growth Company Fund

                  •  

                    1,161,700

                  • 0.00

                  • 2.20

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,062,677

                  • 0.00

                  • 2.01

                  • iShares Core S&P Small-Cap (AU)

                  •  

                    943,509

                  • 0.20

                  • 1.73

                  • Vanguard Small Cap Index

                  •  

                    827,246

                  • 0.04

                  • 1.57

                  • Vanguard Total Stock Mkt Idx

                  •  

                    783,066

                  • 0.00

                  • 1.48

                  • iShares Russell 2000 (AU)

                  •  

                    718,429

                  • -1.46

                  • 1.32

                  • iShares Nasdaq Biotechnology

                  •  

                    683,272

                  • -0.47

                  • 1.25

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    3,114,017

                  • -2.89%

                  • 5.90

                  • BlackRock Fund Advisors

                  •  

                    3,012,595

                  • -5.53%

                  • 5.71

                  • Fidelity Management and Research Company

                  •  

                    2,900,314

                  • -6.19%

                  • 5.50

                  • PRIMECAP Management Company

                  •  

                    2,670,600

                  • +23.67%

                  • 5.06

                  • T. Rowe Price Associates, Inc.

                  •  

                    2,618,312

                  • -20.15%

                  • 4.96

                  • SAC Capital Advisors, LP

                  •  

                    2,395,088

                  • +17.31%

                  • 4.54

                  • Discovery Capital Management LLC

                  •  

                    2,377,513

                  • +17.26%

                  • 4.51

                  • State Street Corp

                  •  

                    1,952,696

                  • -4.65%

                  • 3.70

                  • Sectoral Asset Management Inc

                  •  

                    1,674,140

                  • +50.72%

                  • 3.17

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Distressed

                  Style

                  Small Value

                  Momenta Pharmaceuticals Inc was incorporated in the state of Delaware in May 2001 under the name of Mimeon, Inc., later changed the name Momenta Pharmaceuticals, Inc. in September 2002. The Company is a biotechnology company operatin...moreg in three product areas: Complex Generics, Biosimilars and Novel Drugs. In Complex Generics product area, the Company develops generic versions of complex drugs that were approved by the United States Food and Drug Administration under New Drug Applications. Enoxaparin Sodium Injection is the Company's first product to receive marketing approval under ANDA. The second complex generic product candidate, M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a complex drug consisting of a synthetic mixture of polypeptide chains. In Biosimila...morers product area, the Company is seeking to develop biosimilar versions of biologic medicines that were approved by the FDA under Biologics License Applications. Biologics are complex mixtures, and the Company unlocks their structural subtleties using an approach that is similar to the one it uses in the development of complex generics. Novel Drugs program uses the established characterization and process engineering capabilities from complex generics and biosimilars programs with a focus on polysaccharides and therapeutic proteins. Momenta were originally founded to develop novel drugs and it remains the long term goal for the Company. As with the complex generics and biosimilars the Company's platform gives a detailed understanding of the complex structures of novel product candidates, their associated manufacturing processes and controls, and the targeted biologic systems. The Company license or own a patent portfolio of over 95 patent families, each of which includes United States patent applications and/or issued patents as well as foreign counterparts. The Company relies on contract manufacturers since it does not own facilities for manufacturing any products.lessless

                  Key People

                  Craig A. Wheeler

                  CEO/Director/President

                  James R. Sulat

                  Chairman of the Board/Director

                  Genesh Venkataraman Kaundinya, PhD

                  Chief Scientific Officer/Co-Founder/Senior VP, Divisional

                  Richard P. Shea

                  CFO/Chief Accounting Officer/Senior VP, Divisional

                  Bruce L. Downey

                  Director

                  • Momenta Pharmaceuticals Inc

                  • 675 West Kendall Street

                  • Cambridge, MA 02142

                  • USA.Map

                  • Phone: +1 617 491-9700

                  • Fax: +1 617 621-0431

                  • momentapharma.com

                  Incorporated

                  2001

                  Employees

                  269

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: